N2O
PreclinicalSmall molecule
N2O is one of 41 small molecule programs targeting Agitation. It is currently in Preclinical.
2
Indications
3
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
332 competitors in Treatment
#DrugCompanyPhaseTrials
1Dexilant
TakedaPreclinical
Alfenta
Jazz PharmaceuticalsPreclinical
Niclocide
BayerPreclinical
Hivid
CConrado Roberto Hoffmann Filho
Preclinical
Valium
Akero TherapeuticsPreclinical
Clomid
FerringPreclinical
Aurlumyn
BBTG International Inc.
Preclinical
Lotemax
PPharmos
Preclinical
Norpramin
VValidus Pharmaceuticals
Preclinical
Barhemsys
Tibotec Pharmaceuticals, IrelandPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Agitation1 trial
Efficacy of Remifentanil in Preventing Emergence Agitation
Recruiting·SSaglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital·N/A·NCT06539013·99 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for N2O. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- TTel-Aviv Sourasky Medical Center